Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Palatin Technologies (NYSE American: PTN) presented preclinical data for PL7737, their oral melanocortin 4 receptor (MC4R) selective agonist for obesity treatment. Studies showed that PL7737 significantly reduced food intake and body weight in diet-induced obese mice, validating its MC4R-mediated effects. The compound demonstrated promising oral bioavailability and lacked erectogenic activity, making it potentially suitable for obesity treatment.
The company plans multiple clinical trials in 2025 for its obesity programs, including novel long-acting MC4R peptide and small molecule compounds. Additionally, Palatin is conducting a Phase 2 trial combining bremelanotide with tirzepatide, with topline results expected in Q1 2025.
Palatin Technologies (NYSE American: PTN) ha presentato dati preclinici per PL7737, il loro agonista selettivo del recettore melanocortin 4 (MC4R) orale per il trattamento dell'obesità. Gli studi hanno dimostrato che PL7737 riduce significativamente l'assunzione di cibo e il peso corporeo in topi obesi indotti da dieta, convalidando i suoi effetti mediati da MC4R. Il composto ha mostrato una promettente biodisponibilità orale e non ha evidenziato attività erettogena, rendendolo potenzialmente adatto per il trattamento dell'obesità.
L'azienda prevede diversi studi clinici nel 2025 per i suoi programmi contro l'obesità, inclusi nuovi peptidi MC4R a lunga durata d'azione e composti a piccole molecole. Inoltre, Palatin sta conducendo uno studio di Fase 2 che combina bremelanotide con tirzepatide, con risultati preliminari attesi nel primo trimestre del 2025.
Palatin Technologies (NYSE American: PTN) presentó datos preclínicos para PL7737, su agonista selectivo del receptor melanocortina 4 (MC4R) oral para el tratamiento de la obesidad. Los estudios mostraron que PL7737 redujo significativamente la ingesta de comida y el peso corporal en ratones obesos inducidos por dieta, validando sus efectos mediado por MC4R. El compuesto demostró una prometedora biodisponibilidad oral y careció de actividad erectógena, lo que lo hace potencialmente adecuado para el tratamiento de la obesidad.
La compañía planea múltiples ensayos clínicos en 2025 para sus programas de obesidad, incluidos nuevos péptidos MC4R de acción prolongada y compuestos de pequeñas moléculas. Además, Palatin está llevando a cabo un ensayo de Fase 2 combinando bremelanotida con tirzepatida, con resultados principales esperados para el primer trimestre de 2025.
팔라틴 테크놀로지스 (NYSE American: PTN)는 비만 치료를 위한 경구용 멜라노코르틴 4 수용체(MC4R) 선택적 작용제인 PL7737의 전임상 데이터를 발표했습니다. 연구에 따르면 PL7737은 식이 유도 비만 쥐에서 음식 섭취량과 체중을 유의미하게 감소시켜 MC4R 매개 효과를 검증했습니다. 이 화합물은 유망한 경구 생체이용률을 보여주었고 발기 유도 활동이 결여되어 있어 비만 치료에 잠재적으로 적합할 수 있습니다.
회사는 비만 프로그램을 위해 2025년에 여러 임상 시험을 계획하고 있으며, 새로운 장시간 작용 MC4R 펩타이드와 소분자 화합물이 포함됩니다. 또한 팔라틴은 브레멜라노타이드와 티르제파타이드를 결합한 2상 시험을 진행 중이며, 주요 결과는 2025년 1분기에 예상됩니다.
Palatin Technologies (NYSE American: PTN) a présenté des données précliniques pour PL7737, leur agoniste sélectif du récepteur de la mélanocortine 4 (MC4R) oral pour le traitement de l'obésité. Les études ont montré que PL7737 réduisait significativement la consommation alimentaire et le poids corporel chez des souris obèses induites par le régime, validant ainsi ses effets médiés par le MC4R. Le composé a montré une biodisponibilité orale prometteuse et n'a pas présenté d'activité érectogène, ce qui le rend potentiellement adapté pour le traitement de l'obésité.
L'entreprise prévoit plusieurs essais cliniques en 2025 pour ses programmes contre l'obésité, y compris de nouveaux peptides MC4R à action prolongée et des composés de petites molécules. De plus, Palatin mène un essai de Phase 2 combinant le bremelanotide avec le tirzepatide, avec des résultats préliminaires attendus au premier trimestre de 2025.
Palatin Technologies (NYSE American: PTN) hat präklinische Daten zu PL7737, einem oralen selektiven Agonisten des Melanocortin-4-Rezeptors (MC4R) zur Behandlung von Adipositas, vorgestellt. Studien zeigten, dass PL7737 die Nahrungsaufnahme und das Körpergewicht bei diätinduzierten fettleibigen Mäusen signifikant reduzierte und somit die MC4R-vermittelten Effekte bestätigte. Die Verbindung zeigte vielversprechende orale Bioverfügbarkeit und fehlte an erectogener Aktivität, wodurch sie potenziell für die Behandlung von Adipositas geeignet sein könnte.
Das Unternehmen plant mehrere klinische Studien im Jahr 2025 für seine Adipositas-Programme, einschließlich neuartiger langwirksamer MC4R-Peptide und kleiner Molekülverbindungen. Darüber hinaus führt Palatin eine Phase-2-Studie durch, die Bremelanotid mit Tirzepatid kombiniert, und die ersten Ergebnisse werden für das erste Quartal 2025 erwartet.
- Successful preclinical results showing significant decrease in food intake and body weight
- Planned advancement to clinical trials in 2025
- Ongoing Phase 2 trial with results expected Q1 2025
- Drug demonstrated desired safety profile without erectogenic activity
- Product still in early preclinical stage
- Clinical trials not yet initiated
- Multiple years away from potential commercialization
Insights
The preclinical data for PL7737, Palatin's oral MC4R agonist, shows promising results in obesity treatment. Key findings include significant decreases in food intake and body weight in diet-induced obese mice, with mechanism validation through MC4R knockout mice studies. The lack of erectogenic activity differentiates it from other MC4R agonists, potentially offering a better safety profile.
The development pipeline includes multiple obesity-focused programs, with clinical trials planned for 2025. Additionally, an ongoing Phase 2 trial combining bremelanotide with tirzepatide (GLP-1/GIP) has completed enrollment, with results expected in Q1 2025. The company's dual approach of developing both peptide and small molecule compounds demonstrates a comprehensive strategy in targeting the MC4R pathway for obesity treatment.
- Oral PL7737 significantly decreased food intake and body weight
- Oral small molecule melanocortin 4 agonist (MC4R) could address unmet needs and challenges of current obesity treatments
- Multiple clinical trials targeted in calendar year 2025 for the Company's obesity programs
The presentation illustrates and summarizes preclinical studies of the effect of orally administered PL7737 on body weight and food intake in diet-induced obese (DIO) mice and MC4R knockout (MC4R-KO) mice. The studies demonstrated that treatment with oral PL7737 significantly decreased food intake and body weight in DIO mice, but not in MC4R-KO mice, validating that decreased food intake and body weight was MC4R mediated. Additionally presented data showed that PL7737 lacked erectogenic activity, which is desirable for the intended indication. PL7737's emerging efficacy and safety profile supports its potential as an effective obesity treatment while minimizing side effects present in other MC4R agonists.
"The promising oral bioavailability and efficacy data highlights our expertise and efforts in melanocortin MC4R drug development," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "There is an unmet medical need for obesity treatments, and an orally active small molecule MC4R agonist could be a promising option for obese patients. We are excited to advance our obesity programs and start clinical trials in 2025 with our novel, long-acting MC4R peptide and small molecule compounds aimed at treating general obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesity."
Palatin is currently conducting a Phase 2 clinical trial with the MC4R agonist bremelanotide in combination with tirzepatide, a GLP-1/GIP. Enrollment is complete, and topline results are expected in the first quarter of calendar year 2025.
The MC4R pathway plays a key role in the regulation of energy storage and food intake. The novel MC4R selective agonists being developed by Palatin could potentially play a vital role in treating obesity as monotherapy and/or combination therapy.
The poster (#627), entitled "Melanocortin Agonist PL7737 Causes Weight Loss and Decreases Food Consumption in Obese Mice," will be presented tomorrow, Tuesday, November 5th, from 2:30 to 3:30 pm Central Time by lead author John H. Dodd, Ph.D., Senior Vice President Research & Development at Palatin Technologies. Obesity Week is being held at the Henry B. Gonzalez Convention Center in
About ObesityWeek
The preeminent international conference for obesity researchers and clinicians, ObesityWeek® is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy. Overcoming obesity requires multi-disciplinary approaches. This is the conference that encompasses the full spectrum of obesity science: from basic science research, to translational research and clinical application, to public policy; from diet, exercise, lifestyle, and psychology to medical and surgical interventions; from pediatric to geriatric to underserved populations. ObesityWeek® 2024 will be held November 2-6 in
About Melanocortin 4 Receptor Agonists Effect on Obesity
Genetic analysis has identified the melanocortin 4 receptor (MC4R) of the paraventricular nucleus of the hypothalamus as playing a central role in appetite regulation. Genetic mutations that inhibit signaling in the MC4R pathway lead to hyperphagia, decreased energy expenditure and early-onset obesity; such mutations have been identified as the cause of several rare genetic obesity disorders. Agouti-related peptide is an endogenous antagonist of the MC4R that works with neuropeptide Y to stimulate appetite, whereas MC4R agonists such as α- and β-melanocyte-stimulating hormone promote satiety. Agonism of the MC4R therefore represents an attractive target for potential obesity treatments.
About Melanocortin Receptor Agonists
The melanocortin receptor ("MCR") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.
Many tissues and immune cells located in the eye (and other places, for example the gut and kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.
About Obesity
Obesity, which is defined as a body mass index (BMI) ≥30 kg/m2, represents a rising worldwide public health concern. Obesity is associated with an increased risk of overall mortality and serious health conditions, including high blood pressure, high cholesterol, type 2 diabetes, coronary heart disease, stroke and certain cancers. Health-related quality of life is significantly lower among adults with obesity, and obesity is associated with increased health care resource use and high economic burden. Safe and effective obesity treatments therefore remain a critical unmet need. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In
About Palatin
Palatin is a biopharmaceutical company developing first-in-class or best-in-class therapies based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.
Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-presents-data-on-novel-melanocortin-4-receptor-selective-oral-small-molecule-pl7737-obesity-program-at-obesityweek-2024-302294651.html
SOURCE Palatin Technologies, Inc.
FAQ
What were the key results of PL7737 in Palatin's (PTN) preclinical studies?
When will Palatin (PTN) begin clinical trials for their obesity programs?
When will Palatin (PTN) release results from their Phase 2 bremelanotide-tirzepatide combination trial?
